Seagen and Nurix Collaborate to Explore DACs as Potential ADC Alternatives
Originally Published 2 years ago — by Endpoints News
Seagen has partnered with Nurix to develop degrader-antibody conjugates (DAC), combining their expertise in antibody-drug conjugates (ADCs) and protein degradation. Seagen will pay $60 million upfront, with the potential for $3.4 billion in milestones and future royalties for Nurix.